Decision to fund MS drug great news for patients – Breen

September 8th, 2015 - Pat Breen

Clare T.D. and Chair of the Joint Oireachtas Committee on Foreign Affairs and Trade Pat Breen T.D. has said the decision by the HSE to approve funding for Fampyra, a drug used to treat Multiple Sclerosis, will have life changing effects.

“This is great news and I very much welcome this decision by the HSE. I have been making representations and working with MS Sufferers to have this drug approved given the positive impact that this drug is having on the lives of many people diagnosed with disease.

“Fampyra has a very positive impact on many people and the decision to fund the drug will change the lives of those people. It helps with mobility and walking speed, and also has an impact on hand function, allowing those with the disease to carry out routine functions much more easily.

“When trials of the drug ended last year the patients who were benefiting from the drug were very concerned that they could not afford to continue paying for it. Both the HSE and the manufacturer, Biogen, have been in negotiations for some time, and this positive outcome is very welcome, as it will benefit many people and have a very positive impact on their everyday lives.”